Eli Lilly Discloses 7 Retatrutide Arrhythmias and 3 Cardiovascular Events in Late-Stage Trial
Updated
Updated · STAT · Jun 6
Eli Lilly Discloses 7 Retatrutide Arrhythmias and 3 Cardiovascular Events in Late-Stage Trial
3 articles · Updated · STAT · Jun 6
Summary
Seven of 403 patients given Eli Lilly's obesity drug retatrutide developed arrhythmias, and three had major cardiovascular complications, while no such events were reported in the placebo group.
The newly released safety and tolerability data were presented at the American Diabetes Association meeting and published in the Lancet, adding detail to scrutiny of Lilly's next-generation weight-loss therapy.
Retatrutide had already shown rapid weight loss and blood-sugar reductions in the late-stage TRANSCEND-T2D-1 study, a notable result because patients with diabetes typically lose less weight on treatment.
The disclosures sharpen the risk-benefit debate around a closely watched obesity drug that Lilly is positioning as a next-generation entrant in the market.
Retatrutide promises record weight loss but risks heart issues. Is this breakthrough drug worth the danger?
Other weight-loss drugs help the heart. Why might Eli Lilly's powerful new drug pose a cardiovascular threat?
Retatrutide’s Triple Agonist Power: 28% Weight Loss, Cardiac Safety Concerns, and the Future of Obesity Treatment
Overview
Eli Lilly's retatrutide is a new 'triple G' drug that targets GLP-1, GIP, and glucagon receptors, showing remarkable efficacy in late-stage clinical trials. It stands out from existing treatments by delivering strong improvements in appetite control and significant reductions in A1C levels. However, recent disclosures have raised concerns about its cardiovascular safety, including increased heart rate and arrhythmia-related events. While its powerful metabolic benefits make it a promising option for obesity and diabetes, ongoing trials are closely monitoring its safety profile to ensure it can be used effectively and safely in clinical practice.